Abstract | OBJECTIVE: Report a double-blind, placebo-controlled study of rituximab in patients with anti-MAG demyelinating polyneuropathy (A-MAG-DP). METHODS: Twenty-six patients were randomized to four weekly infusions of 375 mg/m(2) rituximab or placebo. Sample size was calculated to detect changes of > or = 1 Inflammatory Neuropathy Course and Treatment (INCAT) leg disability scores at month 8. IgM levels, anti-MAG titers, B cells, antigen-presenting cells, and immunoregulatory T cells were monitored every 2 months. RESULTS: Thirteen A-MAG-DP patients were randomized to rituximab and 13 to placebo. Randomization was balanced for age, electrophysiology, disease duration, disability scores, and baseline B cells. After 8 months, by intention to treat, 4 of 13 rituximab-treated patients improved by > or = 1 INCAT score compared with 0 of 13 patients taking placebo (p = 0.096). Excluding one rituximab-randomized patient who had normal INCAT score at entry, and thus could not improve, the results were significant (p = 0.036). The time to 10m walk was significantly reduced in the rituximab group (p = 0.042) (intention to treat). Clinically, walking improved in 7 of 13 rituximab-treated patients. At month 8, IgM was reduced by 34% and anti-MAG titers by 50%. CD25+CD4+Foxp3+ regulatory cells significantly increased by month 8. The most improved patients were those with high anti-MAG titers and most severe sensory deficits at baseline. INTERPRETATION:
Rituximab is the first drug that improves some patients with A-MAG-DP in a controlled study. The benefit may be exerted by reducing the putative pathogenic antibodies or by inducing immunoregulatory T cells. The results warrant confirmation with a larger trial.
|
Authors | Marinos C Dalakas, Goran Rakocevic, Mohammad Salajegheh, James M Dambrosia, Angelika F Hahn, Raghavan Raju, Beverly McElroy |
Journal | Annals of neurology
(Ann Neurol)
Vol. 65
Issue 3
Pg. 286-93
(Mar 2009)
ISSN: 1531-8249 [Electronic] United States |
PMID | 19334068
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Murine-Derived
- Immunoglobulin M
- Immunologic Factors
- Myelin-Associated Glycoprotein
- Rituximab
|
Topics |
- Aged
- Antibodies, Monoclonal
(therapeutic use)
- Antibodies, Monoclonal, Murine-Derived
- B-Lymphocytes
(drug effects)
- Demyelinating Diseases
(complications, immunology)
- Double-Blind Method
- Female
- Follow-Up Studies
- Humans
- Immunoglobulin M
(blood)
- Immunologic Factors
(therapeutic use)
- Male
- Middle Aged
- Myelin-Associated Glycoprotein
(immunology)
- Polyneuropathies
(complications, immunology)
- Rituximab
- Seveso Accidental Release
- T-Lymphocytes
(drug effects)
- Treatment Outcome
|